This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Feasibility of Radiofrequency Ablation in the Management of Papillary Thyroid Cancer Under Ultra-Sound Guidance.

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified September 2006 by Johns Hopkins University.
Recruitment status was:  Not yet recruiting
Information provided by:
Johns Hopkins University Identifier:
First received: September 26, 2006
Last updated: NA
Last verified: September 2006
History: No changes posted
To study the feasibility of Radiofrequency ablation (RFA) via ultrasound guidance in the treatment of papillary thyroid cancer (PTC).

Condition Intervention
Papillary Thyroid Cancer Procedure: Ultra-sound guided radio-frequency ablation

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Feasibility of Radio-Frequency Ablation in the Management of Papillary Thyroid Cancer Under Ultra-Sound Guidance

Resource links provided by NLM:

Further study details as provided by Johns Hopkins University:

Primary Outcome Measures:
  • After the procedure, each patient will have his/her routine post-operative care and the follow up visits for surgery, without additional specified visits or procedures for the study
  • Patients will be examined for any possible complications at the time of surgery.

Secondary Outcome Measures:
  • Patients will be followed-up accordingly for any complications.

Estimated Enrollment: 20
Study Start Date: November 2006
Estimated Study Completion Date: November 2008
Detailed Description:

Around 23,000 cases of thyroid cancer are discovered annually in the US, and PTC accounts for 70-75% of those cases. The conventional treatment consists mainly of surgical resection, in the form of lobectomy with/without isthmusectomy, or total thyroidectomy, making it one of the most commonly performed procedures. It has high costs, and exposes the patients to morbidity of surgery and anesthesia. PTC tends to be indolent with a 90% cure rate and controversy exists regarding extent of treatment.

Percutaneous image-guided RFA has received increasing attention as a promising minimally invasive technique for the treatment of focal malignant disease. It permits the in situ destruction of tumors without necessitating their surgical excision.


Ages Eligible for Study:   18 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Aged 18-90 years old
  • Patients with low risk well-differentiated PTC, diagnosed by US guided FNA, and whose management decision is total thyroidectomy.
  • Patients with only one dominant malignant nodule will be included in the study.
  • Patients with size of their thyroid nodule ranging only between 1-4cm in diameter will be included in the study.
  • Patients with nodules located only in between the mid and lower pole of the thyroid gland will be included in the study.

Exclusion Criteria:

  • When the patient does not meet the inclusion criteria.
  • When the patient has a contra-indication of surgery or anesthesia.
  • If the patient refuses involvement in the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00381225

Contact: Tarik Farrag, M.D 410-955-3628

United States, Maryland
Johns Hopkins University, School of Medicine Not yet recruiting
Baltimore, Maryland, United States, 21287
Sponsors and Collaborators
Johns Hopkins University
Principal Investigator: Kieran Murphy, M.D Johns Hopkins University
  More Information Identifier: NCT00381225     History of Changes
Other Study ID Numbers: NA_00002641
Study First Received: September 26, 2006
Last Updated: September 26, 2006

Keywords provided by Johns Hopkins University:

Additional relevant MeSH terms:
Thyroid Diseases
Thyroid Neoplasms
Endocrine System Diseases
Endocrine Gland Neoplasms
Neoplasms by Site
Head and Neck Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type processed this record on August 18, 2017